| Theme | Recent advance in the treatment of IBD based on the pathogenesis | |
|---|---|---|
| Title | Usefulness of budesonide foam for ulcerative colitis treatment | |
| Publish Date | 2018/05 | |
| Author | Makoto Naganuma | Division of Gastroenterology and Hepatology, School of Medicine, Keio University |
| Author | Takanori Kanai | Division of Gastroenterology and Hepatology, School of Medicine, Keio University |
| [ Summary ] | For treatment of ulcerative proctitis/proctsigmoiditis of mild to moderate severity, the first choice is topical therapy. However, because of a lack of knowledge and familiarity regarding efficacy, safety, and patient tolerance, topical therapies are often underused for UC patients. Budesonide foam has been developed as a topical therapy with high tolerability and few side effects. Two clinical trials in Japan have confirmed that a high complete mucosal cure rate can be obtained by treating with budesonide foam twice a day for six weeks. As a result, budesonide foam has been used since December 2017. While it is considered to be a treatment for cases in which topical therapy has become refractory, it should also be noted that adverse effects exist, such as the suppression of serum cortisol. | |